On an uptrend near the 210-day MA (30 weeks) (Wall around €5). Key takeaways:
- Clinical advances on lanifibranor
- Financing and partnerships (including rumors from US pharmaceutical giants)
- Cash flow increasing until mid-2026.
Analysts' speculative price target around €8. Everything will depend on the feedback from lanifibranor's advances. The Chinese paid $10 million as part of a partnership. I have a PRU of €2.93. I'm sticking with this company for the long term.
- Clinical advances on lanifibranor
- Financing and partnerships (including rumors from US pharmaceutical giants)
- Cash flow increasing until mid-2026.
Analysts' speculative price target around €8. Everything will depend on the feedback from lanifibranor's advances. The Chinese paid $10 million as part of a partnership. I have a PRU of €2.93. I'm sticking with this company for the long term.
Exención de responsabilidad
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Exención de responsabilidad
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.